Manba Finance shares listed at Rs 150 on the BSE, a 25% premium over the issue price. The IPO received overwhelming subscription with 223.12 times oversubscription.

Manba Finance's IPO received an overwhelming response, with bids exceeding the offer by 223.12 times. The IPO, valued at Rs 151 crore, saw strong participation from all investor categories.

Manba Finance's IPO received heavy subscription on day 2, reaching 73.18 times. Institutional investors led the demand, with the IPO closing on September 25.

Manba Finance IPO received 23.67 times subscription on Day 1, with strong demand from retail and non-institutional investors. The IPO, priced at Rs 114-120 per share, will conclude on September 25.

Manba Finance's IPO, worth Rs 151 crore, opens on September 23. The price band has been set at Rs 114-120 per share. Proceeds will be used for lending and general corporate purposes.

Dr Agarwal's Healthcare, backed by Temasek and TPG, files IPO papers to raise Rs 3,000-3,500 crore. The IPO includes a fresh issue and an offer for sale by promoters.

Venus Remedies has obtained marketing authorisations for carboplatin and bortezomib in Morocco and Philippines, respectively, expanding its oncology portfolio and presence in Southeast Asia and...

The income tax department has extended the deadline for filing audit reports for 2023-24 to October 7, citing difficulties faced by taxpayers in electronic filing.

Indian stock markets decline in early trade due to foreign fund outflows and weak Asian markets. Sensex and Nifty drop sharply. Read more.

BharatPe and Ashneer Grover have reached a settlement, ending his association with the company. Grover will not hold any shares or positions.

Dr Agarwal's Healthcare, backed by Temasek and TPG, files IPO papers to raise Rs 3,000-3,500 crore. The IPO includes a fresh issue and an offer for sale by promoters.

India's consumer durables market is poised to become the world's 4th largest by 2027, with a projected size of Rs 5 lakh crore by FY30, according to CII. The sector is expected to see significant...

Venus Remedies has obtained marketing authorisations for carboplatin and bortezomib in Morocco and Philippines, respectively, expanding its oncology portfolio and presence in Southeast Asia and...

Asian markets saw a wild start to the week, with Tokyo's Nikkei 225 index tumbling nearly 5% while Chinese markets soared on news of fresh stimulus for the faltering economy. Learn more about the...

China's economy weakened further in recent weeks, as factory surveys show a decline in manufacturing orders. Beijing has stepped up stimulus measures to support the economy.